340B Hospitals May Be Losing Transparency Debate In Congress

Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.

Hand holds the magnifying glass in front of an open notebook. Among the many icons, attention is focused on the money icon. Financial operations, banking, lending, etc.

Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., is frustrated with arguments by safety net hospitals that they should not be required to disclose how they use the savings from outpatient drug discounts provided under the 340B program.

At a March 15 committee hearing he also focused attention on whether the discounts are going toward reducing the cost...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access